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delay ranged from 7 to 104 minutes, while absolute survival benefit ranged from –4
(favoring Rx) to 15 (favoring PTCA). The survival benefit decreased as the PTCA-related
delay increased (figure). After the exclusion of AIR PAMI trial (longest delay and high risk
patients) equivalence of survival rates between PTCA and Rx was reached for a PTCA
related delay of 63 minutes: change in benefit per 10-minutes delay was 1 % (P=0.01). In
clinical trials with short PTCA-related delays, PTCA produced better outcomes, while tri-
als with longer delays favored Rx. At experienced institutions and for high risk patients,
however, PTCA is probably still preferable, even when delay is longer.
1022-85 Glucose-Insulin-Potassium Infusion Improves 
Myocardial Salvage in Diabetic Patients With Acute 
Myocardial Infarction Treated With Reperfusion Therapy
Jürgen Pache, Joerg Hausleiter, Adnan Kastrati, Julinda Mehilli, Hildegard Bolwein, 
Helmut Schühlen, Josef Dirschinger, Albert Schoemig, 1. Medizinische Klinik rechts der 
Isar, Munich, Germany, Deutsches Herzzentrum Muenchen, Munich, Germany
Patients (pts) with acute myocardial infarction (AMI) who receive reperfusion therapy
might have some benefit from glucose-insulin-potassium infusion (GIK). GIK is expected
to enhance myocardial salvage obtained with reperfusion. The objective of this subgroup
analysis of the randomized Reevaluation of Intensified Venous Metabolic Support for
Acute Infarct Size Limitation (REVIVAL) trial was to assess whether GIK improves myo-
cardial salvage in various subsets of pts.
We randomized 312 patients with AMI to receive either GIK infusion for 24 hours (GIK
group, n=155) or no GIK (control group, n=157). The primary endpoint of the study was
salvage index (proportion of myocardium at risk salvaged by therapy) as measured by
technetium Tc 99m sestamibi scintigraphic studies performed before and 7-10 days after
therapy. Various subsets of pts (fig) were analyzed according to their difference in sal-
vage index.
In the overall pts group salvage index was 0.5 in the GIK group and 0.48 in the control
group (p=0.96). The subgroup analysis is shown in the figure.
The results of this subgroup analysis demonstrate that GIK enhance myocardial salvage
only in pts with diabetes. 
1022-86 Association of Inflammation and Benefit of Statins in 
Patients With Acute Myocardial Infarction
Kunihiro Kinjo, Hiroshi Sato, Yozo Ohnishi, Eiji Hishida, Daisaku Nakatani, Hiroya 
Mizuno, Masahiko Shimizu, Masatsugu Hori, Osaka University Graduate School of 
Medicine, Suita, Japan
Background _ Inflammation as detected by elevated C-reactive protein (CRP) levels
predicts the risk of coronary events. The effect of inflammation on coronary risk has
shown to be attenuated by statin therapy in patients with stable coronary artery disease.
However, this effect of statin therapy for acute myocardial infarction (AMI) is unknown.
Methods and Results _ We studied 3508 survived AMI patients who enrolled in Osaka
Acute Coronary Insufficiency Study. CRP was measured during the stable phase (mean,
21 days after the onset). Patients with statin treatment at discharge had a lower 1-year
mortality than those without statin treatment (1.1% versus 3.2%, log rank, p<0.001). Mul-
tivariate Cox regression analysis revealed that statin treatment remained predictive of a
lower 1-year mortality rate (hazard ratio (HR), 0.38; 95% confidence interval (CI), 0.15-
0.96). Although the 1-year mortality was not different among patients with and without
statin treatment in patients with low CRP, the 1-year mortality was higher in the patients
without statin treatment than in those with statin treatment in patients with high CRP. In
the presence of statin therapy, the HR for 1-year mortality was significantly reduced in
patients with high CRP (HR, 1.46, 95% CI, 0.15-14.5) to about the same degree as in
patients with low CRP and who did not receive statin therapy (HR, 2.53; 95% CI, 0.46-
13.8).
Conclusions _ Statin treatment at discharge is associated with reduced 1-year mortality
of patients with AMI. Furthermore, statin treatment significantly attenuates the increased
risk for 1-year mortality in patients with AMI. Measurement of CRP levels may improve
targeting of statin therapy in patients with AMI.
1022-87 Improvement of Long-Term Outcome in Acute 
Myocardial Infarction Over Time: Experiences From the 
Register of Information and Knowledge About Swedish 
Heart Intensive Care Admissions
Ulf Stenestrand, Lars Wallentin, Heart Center, University Hospital, Linkoping, Sweden, 
UCR, University Hospital, Uppsala, Sweden
Background: During the last years several new therapies, some very costly, have proven
in clinical trials to improve survival in patients with acute myocardial infarction (AMI). The
aim of this study was to evaluate if these new therapies have changed long term outcome
in a non selected CCU population of daily care patients.
Methods & Results: All patients admitted to participating CCUs were included. Clinical
background, admission status, medications, interventions, complications were recorded
for the years 1995-2001 including 1 year follow-up until the end of 2002 in 90% of the
Swedish hospitals. Among the CCU patients there were 73828 with AMI. In hospital and
long term mortality decreased for each studied year. The Kaplan-Meier curves indicate
that during the study period 1-year mortality has sunken from 21% to 16% in patients 66-
75 years (figure 1), 9% to 6% in patients below 65 years, and 39% to 35% in patients
older than 75 years.
Conclusion: This analysis supports that new therapies have helped to improve 1-year
survival in not only in selected trial patients but also in an unselected cohort of daily CCU
patients of all ages with AMI.
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1023-89 Chelation Therapy for Patients With Coronary Heart 
Disease: Findings From the Pilot to Assess Chelation 
Therapy
Gervasio A. Lamas, Alan Ackermann, Danielle Hollar, Paul Kurlansky, Joseph Vita, 
Charles H. Hennekens, Mount Sinai Medical Center-Miami Heart Institute, Miami Beach, 
FL, Boston University School of Medicine, Boston, MA
Background: Chelation therapy involves a series of intravenous infusions of dsodium
EDTA. Despite widespread use for the treatment of coronary heart disease (CHD), ran-
domized data on safety and benefits are relatively sparse. The Pilot for the Trial to Assess
Chelation Therapy (PACT) was a randomized, double-blind, placebo-controlled trial, com-
paring EDTA chelation with placebo infusions.
Methods: PACT randomized and followed 40 patients, 30 assigned to chelation therapy
infusions, and 10 to placebo infusions. All patients received 15 weekly infusions of chela-
tion or normal saline, plus low-dose vitamin supplementation. Laboratory safety data
were compared between groups on the last day of infusion. We also performed
endothelial function studies using brachial artery flow-mediated dilation expressed as
percent above baseline (FMD %).
Results: On the day of the last infusion, there were no significant differences between
the chelation and placebo groups for: creatinine (1.1 v 1.1), glucose (112 v 134), hemat-
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ocrit (53 v 41), magnesium (2.1 v 2.0), platelet count (209,000 v 209,000), potassium (4.4
v 4.7), calcium (9.4 v 9.4), SBP during infusion (118 v 128). Change in FMD from base-
line to 15th infusion was not significantly different between groups (∆ FMD % chelation:
mean = 2.39; ∆ FMD % placebo: mean = -.53, p=.453).
Conclusions: PACT provides reassuring randomized data concerning a large number of
safety parameters monitored over a 15-week course of chelation therapy with EDTA. The
most reliable data concerning the safety and efficacy of chelation therapy for patients
with CHD will emerge from the NIH-funded Trial to Assess Chelation Therapy (TACT),
which will randomize 2,372 patients in a 2x2 factorial trial of EDTA and/or high-dose vita-
mins.
1023-90 Effects of Nitroglycerin on Erythrocyte Rheology and 
Oxygen Unloading: Microvascular Mechanisms in 
Relieving Myocardial Ischemia
Jian-Ping Bin, Howard Leong-Poi, Nicholas G. Fisher, D. Elizabeth Le, Jonathan 
Christiansen, Sanjiv Kaul, University of Virginia, Charlottesville, VA
Purpose: We hypothesized that myocardial blood flow (MBF) is enhanced to ischemic
tissue by the direct effect of nitroglycerin (NTG) on erythrocyte rheology and that anti-
ischemic effects of NTG are also afforded by its direct effects on O2 unloading .
Background: Investigations of the anti-ischemic properties of NTG, have been generally
focused on its systemic and coronary hemodynamic effects. At the microcirculatory level,
however, erythrocyte rheology and O2 unloading play an important role in determining
MBF and O2 delivery, respectively.
Methods and Results: Twelve dogs were studied at rest and during direct intracoronary
infusion of NTG (0.3-0.6µg·kg-1·min-1). All dogs had a resting flow-reducing single-vessel
stenosis. Half the dogs also had total occlusion of the remote coronary artery to remove
any collateral effects. Hemodynamics, MBF, WBη, erythrocyte charge (EC) and electroki-
netic mobility (EM), regional myocardial O2 delivery and consumption as well as tissue
O2 pressure (PO2) were determined. As compared to baseline, no changes in hemody-
namics were seen during intracoronary NTG. MBF increased significantly in the central
25% of the myocardium supplied by stenosis, which was associated with an approxi-
mately 19% decrease in WBη. There was a good correlation (r=0.87) between the two.
The decrease in WBη was caused by a decrease in EC and an increase in EM (r=0.83).
As compared to baseline, the % increase in tissue PO2 was significantly greater during
NTG than the % increase in MBF, indicating enhanced O2 unloading.
Conclusions: NTG directly affects microcirculatory erythrocyte rheology that is associ-
ated with an increase in MBF in the center of the ischemic bed. It also directly enhances
O2 unloading to the ischemic myocardium. Thus, direct microvascular affects of NTG
also contribute to its anti- ischemic properties.
1023-91 Relationship Between β-Adrenergic System 
Polymorphisms and Coronary Peak Flow Velocity Ratio 
in Women: Analysis From the National Heart, Lung, and 
Blood Institute-Sponsored Women's Ischemia 
Syndrome Evaluation (WISE)
Issam Zineh, Susan P. McGorray, Lacy L. Jernigan, Dennis M. McNamara, Daniel F. 
Pauly, C. Noel Bairey Merz, Carl J. Pepine, Julie A. Johnson, University of Florida, 
Gainesville, FL
Background: Coronary microvascular dysfunction is frequent in women presenting with
ischemic symptoms, but the pathophysiological basis is unclear. Genetic polymorphisms
in the adrenergic system were evaluated to gain insight into possible pathophysiological
mechanisms.
Methods: We studied WISE participants who underwent coronary angiography for evalu-
ation of ischemic symptoms. Angiography with Doppler ultrasonography was used to
measure average peak velocity ratio (APV-R) response to adenosine (Ad), acetylcholine
(Ach), and nitroglycerin (NTG). Patients were genotyped for polymorphisms of the β1-
adrenergic receptor (AR) (codons 49 and 389), β2AR (codons 16 and 27), and Gsα
(codon 131) using single-primer extension or luciferase-based assays. ANOVA and t-
tests were performed to compare the reactivity parameters by genotype. Data are pre-
sented as means ± SD. Due to significant differences in variant alleles by race, p-values
were adjusted for genotype-by-race interaction.
Results: Polymorphisms in the β1AR, β2AR, and Gsα were associated with differences in
APV-R response to NTG. Ser49 homozygotes (n=69) had diminished response com-
pared with Gly49 carriers (n=34), with APV-R of 2.14 ± 0.58 and 2.47 ± 0.62, respectively
(p=0.039). APV-R at codon 16 for Arg16Arg (n=26), Arg16Gly (n=48), and Gly16Gly
(n=29) were 2.27 ± 0.58, 2.33 ± 0.65, and 2.11 ± 0.59 (p=0.029). APV-R at codon 27 for
Gln27Gln (n=45), Gln27Glu (n=50), and Glu27Glu (n=9) were 2.28 ± 0.63, 2.32 ± 0.61,
and 1.82 ± 0.36, respectively (p=0.039). Finally, at Gsα codon 131, APV-R for +/+ (n=23),
+/- (n=51), and -/- (n=29) were 2.52 ± 0.62, 2.19 ± 0.65, and 2.19 ± 0.53 (p=0.036). β1AR
codon 389 (Arg◊Gly) was not associated with APV-R response to NTG in this population
(p=0.18). There were no associations between any genotypes and reactivity response to
Ad or Ach.
Conclusion: Polymorphisms in βARs and their G protein are associated with differences
in APV-R response to NTG in women undergoing angiography for evaluation of ischemic
symptoms. These data indicate a potential role of the adrenergic system in microvascular
dysfunction.
1023-92 Potential Beneficial Effects of Transdermal Capsaicine 
Patches on the Ischemic Threshold in Patients With 
Stable Coronary Disease
Gabriele Fragasso, Altin Palloshi, Maria Luisa De Benedictis, PierMarco Piatti, Lucilla 
Monti, Emanuela Setola, Alberto Cappelletti, Alberto Margonato, Istituto Scientifico/
Universita' San Raffaele, Milano, Italy
Background. Capsaicin has been shown to exert direct vasodilating effects through
increased calcitonine gene-related peptide (CGRP) release. However no data exist on its
effect following systemic administration.
Methods. Twelve male patients with stable coronary disease were selected for study. All
patients had a persistently positive exercise test despite full antianginal therapy. Accord-
ing to a double blind, placebo-controlled study, patients were randomised to placebo or
3g oleic capsaicin-containing patches, in 2 different days and with a 2-day interval
between treatments. Patients performed treadmill exercise testing according to the Bruce
protocol. Heart rate, systolic/diastolic blood pressure and rate-pressure product were
measured at rest, at the appearance of 1mm ST segment depression and at peak exer-
cise. Time to 1mm ST segment depression and to peak exercise, maximal ST segment
depression, cumulative maximal ST segment depression and the number of ECG leads
showing diagnostic changes were also measured. Blood samples for nitric oxide (NO)
and CGRP were drawn at baseline, at peak exercise, 2, 6 and 24 hours after exercise.
Results. On placebo, all patients had a positive ECG during exercise test. Only one
patient experienced angina, in both treatments. With capsaicin, 1 patient had a negative
exercise, while the remaining 11 increased time to 1mm ST depression (from 372±170 to
424±182 sec, p<0.03) and time to peak exercise (from 489±189 to 508±202 sec, p=0.29)
and decreased the total number of involved ECG leads (from 3.75±1.76 to 3.25±2.00
leads, p=0.05). CGRP levels were not significantly different between placebo and capsa-
icin treatment. Conversely, when on capsaicin, NO significantly increased at 6 hours. No
significant side effects were recorded. Conclusions. Transdermal capsaicin may
improve ischemic threshold in patients with stable coronary disease, probably through
NO-mediated arteriolar vasodilation
1023-93 Anti-Inflammatory Effects of the V-Protectant AGI-1067 
in the Canadian Antioxidant Restenosis Trial (CART-1)
Jean-Claude Tardif, Philippe L. L'Allier, Leonard Schwartz, Lawrence Title, Louise 
Laramee, Francois Reeves, Joel Lavoie, Marie-Claude Guertin, Jean Gregoire, Montreal 
Heart Institute, Montreal, PQ, Canada
AGI-1067, the mono-succinic acid ester of probucol, is a lipophilic vascular protectant
that reduces the expression of VCAM-1 and MCP-1 and has strong antioxidant proper-
ties equipotent to probucol. We have shown in CART-1 that AGI-1067 has favorable
effects on restenosis and the atherosclerotic non-PCI (reference) segments (Circulation
2003;107:552-8). The objective of the present study was to determine the effects of AGI-
1067 on markers of inflammation. Prior to PCI, 305 pts were randomly assigned to 1 of 5
treatment groups: placebo (n=61); probucol 500 mg BID (n=60); AGI-1067 70 mg (n=59),
140 mg (n=64), or 280 mg (n=61) QD. Pts were treated for 2 wks prior to and for 4 wks
after PCI. Fibrinogen plasma levels and circulating white blood cell (WBC) counts were
measured at baseline and at the end of the 6-wk dosing period. Results: Plasma levels of
fibrinogen at baseline were 3.73+/-1.29 in the placebo group, 3.70+/-0.98 in the probucol
group, and 3.63+/-1.13, 3.78+/-0.81 and 3.70+/-0.83 gm/L in the AGI-1067 70, 140 and
280 mg groups respectively (p=NS). After 6 wks of treatment, fibrinogen levels were
3.56+/-0.76 in the placebo group, 3.63+/-1.05 in the probucol group, and 3.37+/-1.17,
3.17+/-0.65 and 3.21+/-1.01 gm/L in the AGI-1067 70, 140 and 280 mg groups respec-
tively (p=0.03 for AGI-1067 140 mg vs placebo; p=0.07 for AGI-1067 280 mg vs placebo;
p=0.005 for AGI-1067 140 mg vs probucol; p=0.017 for AGI-1067 280 mg vs probucol).
WBC counts decreased from baseline to end of treatment by 0.51+/-1.31 in the placebo
group, 0.79+/-1.48 in the probucol group, and 0.59+/-2.06, 0.88+/-1.40 and 1.09+/-1.26 in
the AGI-1067 70, 140 and 280 mg groups respectively (p=0.025 for AGI-1067 280 mg vs
placebo; p=NS for probucol vs placebo). Fibrinogen levels after 6 wks of treatment corre-
lated inversely (p=0.07) with the previously described favorable effect induced by AGI-
1067 in atherosclerotic reference segments as assessed by intravascular ultrasound.
Conclusion: The vascular protectant/antioxidant AGI-1067 has anti-inflammatory effects
in patients with atherosclerosis. The CART-2 and ARISE (Aggressive Reduction of
Inflammation Stops Events) trials are testing the anti-inflammatory hypothesis with AGI-
1067.
1023-94 Comparative Effect of Trimetazidine Plus Sildenafil 
Versus Nitrates in the Control of Myocardial Ischemia 
During Sexual Activity
Giuseppe M. Rosano, Roberto Patrizi, Giuseppe Marazzi, Elena Cerquetani, Massimo 
Fini, Giuseppe Mercuro, San Raffaele Roma, Roma, Italy, University of Cagliari, Cagliari, 
Italy
A large proportion of patients with erectile dysfunction (ED) have coronary artery disease
(CAD). In these patients nitrate therapy that is a contraindication to the use of Sildenafil.
In order to assess whether trimetazidine is effective in controlling episodes of myocardial
ischemia during sexual activity in patients with (CAD) receiving chronic nitrates we stud-
ied 38 male patients (57+6 years) with proven CAD. Patients underwent 24 hour ECG
monitoring (AEM) at baseline, after one week of oral nitrate therapy (20 mg tds) and after
one week of Trimetazidine (20 mg tds). Patients were asked to have at least one sexual
intercourse during each AEM. Patients were instructed to take Sildenafil (100 mg) one
hour before the sexual intercourse performed at baseline and during therapy with Tri-
metazidine and Sildenafil Placebo (in blind) during therapy with nitrates. An improvement
in total ischemic burden was observed with both nitrates and Trimetazidine compared to
baseline (-3+2 vs –5+3 episodes/24 hours, p=0.07; -6+5 vs –8+3 minutes/24 hours,
p=0.07). Trimetazidine plus Sildenafil were more effective in controlling episodes of myo-
